Orchid Pharma Board Approves Enabling ₹600 Crore Fund Raise Plan

Board passed enabling resolution on 20 Oct 2026 to explore fundraise up to Rs 600 Cr via equity, convertibles, QIP, public, preferential or other modes, subject to approvals. Follows prior QIP-funded build phase; comes while Jammu 7ACA and cefiderocol capex still underway with project debt being drawn and prior QIP funds partly undeployed. Enabling only; instrument, pricing, timeline, use of proceeds and dilution undisclosed; needs shareholder and regulatory nods; creates dilution overhang.